Surmodics, Inc.
SRDXNASDAQHealthcare
$42.98
+$0.15(+0.35%)
Market Cap$614511837
P/E Ratio—
52W High$43.0048
52W Low$25.87
Surmodics, Inc. (SRDX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SRDX · earnings · updated Jun 8, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 8, 2025EPS Actual
$0.06
Est. -$0.21 · +128.6%
Revenue
$0.03B
Est. $0.03B · -1.4%
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 8, 2025
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
SRDX reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Apr 28, 2026 | — | — | — | — | — | — |
| ◌ Q4 FY2025 | Dec 3, 2025 | -$0.18 | — | — | — | $0.03B | — |
| ◌ Q4 FY2025 | Nov 26, 2025 | -$0.19 | — | — | — | $0.03B | — |
| ▲ Q3 FY2025 | Aug 8, 2025 | -$0.21 | $0.06 | +128.6% | $0.03B | $0.03B | -1.4% |
| ▼ Q2 FY2025 | Apr 30, 2025 | -$0.06 | -$0.13 | -116.7% | $0.03B | $0.03B | -12.9% |
| ▲ Q1 FY2025 | Jan 30, 2025 | -$0.12 | -$0.04 | +66.7% | $0.03B | $0.03B | -10.3% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.27 | -$0.13 | +51.9% | $0.03B | $0.03B | +9.3% |
| ▲ Q3 FY2024 | Jul 31, 2024 | -$0.31 | -$0.27 | +12.9% | $0.03B | $0.03B | -0.2% |
Q2 FY2026
Apr 28, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Dec 3, 2025
EPS Actual
—
EPS Est.
-$0.18
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 26, 2025
EPS Actual
—
EPS Est.
-$0.19
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 8, 2025Beat
EPS Actual
$0.06
EPS Est.
-$0.21
EPS Surpr.
+128.6%
Revenue
$0.03B
Q2 FY2025
Apr 30, 2025Miss
EPS Actual
-$0.13
EPS Est.
-$0.06
EPS Surpr.
-116.7%
Revenue
$0.03B
Q1 FY2025
Jan 30, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.12
EPS Surpr.
+66.7%
Revenue
$0.03B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.13
EPS Est.
-$0.27
EPS Surpr.
+51.9%
Revenue
$0.03B
Q3 FY2024
Jul 31, 2024Beat
EPS Actual
-$0.27
EPS Est.
-$0.31
EPS Surpr.
+12.9%
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $0.06 | $0.06 | $0.06 | 1 |
| Q2 FY2026 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q1 FY2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q4 FY2025 | $-0.18 | $-0.18 | $-0.18 | 2 |
| Q3 FY2025 | $-0.19 | $-0.19 | $-0.19 | 2 |
| Q2 FY2025 | $-0.18 | $-0.18 | $-0.16 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2025 | Aug 8, 2025 | +128.6% | $35.01 | $35.41 | +1.14% |
| ▼ Q2 FY2025 | Apr 30, 2025 | -116.7% | $30.93 | $28.01 | -9.44% |
| ▲ Q1 FY2025 | Jan 30, 2025 | +66.7% | $35.78 | $35.48 | -0.84% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +51.9% | $37.66 | $38.49 | +2.20% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +12.9% | $41.50 | $41.40 | -0.24% |
| ▲ Q2 FY2024 | May 1, 2024 | +119.4% | $25.69 | $33.33 | +29.74% |
| ▲ Q1 FY2024 | Feb 1, 2024 | +81.4% | $35.21 | $32.43 | -7.90% |
| ▲ Q4 FY2023 | Nov 8, 2023 | +178.9% | $30.96 | $33.24 | +7.36% |
Q3 FY2025+1.14%
Report Date
Aug 8, 2025
EPS Beat/Miss
+128.6%
Price Before
$35.01
Price After
$35.41
Q2 FY2025-9.44%
Report Date
Apr 30, 2025
EPS Beat/Miss
-116.7%
Price Before
$30.93
Price After
$28.01
Q1 FY2025-0.84%
Report Date
Jan 30, 2025
EPS Beat/Miss
+66.7%
Price Before
$35.78
Price After
$35.48
Q4 FY2024+2.20%
Report Date
Nov 6, 2024
EPS Beat/Miss
+51.9%
Price Before
$37.66
Price After
$38.49
Q3 FY2024-0.24%
Report Date
Jul 31, 2024
EPS Beat/Miss
+12.9%
Price Before
$41.50
Price After
$41.40
Q2 FY2024+29.74%
Report Date
May 1, 2024
EPS Beat/Miss
+119.4%
Price Before
$25.69
Price After
$33.33
Q1 FY2024-7.90%
Report Date
Feb 1, 2024
EPS Beat/Miss
+81.4%
Price Before
$35.21
Price After
$32.43
Q4 FY2023+7.36%
Report Date
Nov 8, 2023
EPS Beat/Miss
+178.9%
Price Before
$30.96
Price After
$33.24
Avg Beat Reaction+4.49%
Avg Miss Reaction-9.44%
Beat Rate7 / 8 quarters
Largest Move+29.74% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SRDX ends December
Surmodics, Inc. (SRDX) most recently reported earnings on August 8, 2025 for Q3 FY2025, posting EPS of $0.06 — beating the analyst consensus of $-0.21 by +128.6%. The next SRDX earnings date is expected around September 1, 2026.
Each quarter, investors track SRDX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SRDX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SRDX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SRDX earnings · 5 questionsSurmodics, Inc.'s next earnings report is expected around September 1, 2026. SRDX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SRDX historically reports after market close (AMC).
SRDX earnings datewhen is SRDX earningsSRDX next earnings datewhen does SRDX report earningsSRDX earnings calendar
▸ Source: FMP · Surmodics, Inc. SEC filings · US GAAP · Surmodics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026